@drmaryclaire: Breaking news in menopause, and it's good news. A Finnish study of more than one million postmenopausal women found that those using low-dose vaginal estradiol had roughly a 15 to 20% lower rate of rectal cancer than non-users. The signal showed up even with just a few years of use. This adds to a growing body of evidence. Studies on systemic estrogen point the same direction, toward lower colorectal and rectal cancer risk, and the large safety cohorts confirm vaginal estrogen does not raise colorectal cancer risk at all. The honest framing, because that is the only kind I do. This is a single observational study, so it shows a strong association, not proof of cause. We want prospective trials to confirm it. But the direction is encouraging, and it sits alongside everything vaginal estrogen already does well: it restores tissue, eases painful sex, calms recurrent UTIs, and protects the urinary tract. You use vaginal estrogen because it gives you back comfort and function. Findings like this one are a welcome bonus on top of a treatment that already earns its place. Menopause is inevitable. Suffering is not. 📚 Siitonen et al., 2025, Maturitas, Finnish nationwide case-control study. Supporting context: Mørch et al. 2016; Liu et al. 2021; Crandall et al. 2017 (WHI Observational Study, no increased colorectal cancer risk). #greenscreensticker

The 'Pause Life

Open In TikTok:

Region: US

Sunday 14 June 2026 16:57:09 GMT